UPDATE
: Monday, September 7, 2020
Home
Login
Mobile Version
All
Hospital
Pharma
Bio
Korea‘s Bio Industry
Device/ICT
Policy
People
Life science
Special
Innovation for Survival
Korea’s medical culture series
Korea’s New Candidate Drug Watch List
Special Series in Celebration of KBR's 1st Anniversary
Interview with foreign envoys
Special Series in Celebration of KBR’s 2nd Anniversary
Interview with global pharma
Special Series in Celebration of KBR’s 3rd Anniversary
Special Series in Celebration of KBR’s 4th Anniversary
ASCO 2020 Highlights
Opinion
Reporter’s Notebook
Search
트위터
페이스북
RSS
상단여백
기사
(전체 190건)
제목보기
제목보기
제목+내용
기사보기
How are Korean drugmakers faring in US?
Major Korean drugmakers ...
So Jae-hyeon
|
2018-05-09 15:55
기사보기
Hanmi wins FDA nod for arthritis treatment Hyalrheuma
Hanmi Pharmaceutical sai...
So Jae-hyeon
|
2018-05-09 11:59
기사보기
Boryung’s antihypertensive drug Kanarb tops output among new drugs
Boryung Pharmaceutical’s...
So Jae-hyeon
|
2018-05-08 16:05
기사보기
Daewoong to seek US nod for liver drug Ursa this year
Daewoong Pharmaceutical ...
So Jae-hyeon
|
2018-05-08 14:37
기사보기
Korean pharma firms target rare diseases to enter US market
Domestic pharmaceutical ...
So Jae-hyeon
|
2018-04-30 16:42
기사보기
Why is Medipost enhancing cord blood biz?
Medipost is aggressively...
So Jae-hyeon
|
2018-04-26 16:44
기사보기
Drugmakers compete to develop liver drugs
Korean pharmaceutical co...
So Jae-hyeon
|
2018-04-20 14:18
기사보기
Blockbuster Remicade losing out to Korean biosimilars in US
Biosimilar drugs develop...
So Jae-hyeon
|
2018-04-19 15:39
기사보기
Pharma sector embraces work-life balance
Some companies in the ph...
So Jae-hyeon
|
2018-04-19 14:25
기사보기
How are Korean drugmakers performing in China?
The pharmaceutical indus...
So Jae-hyeon
|
2018-04-17 15:12
기사보기
Will anti-smoking drug Champix still be champion?
Korean drugmakers are ex...
So Jae-hyeon
|
2018-04-16 14:46
기사보기
SillaJen reveals clinical results on Pexa-Vec in UK
SillaJen said it unveile...
So Jae-hyeon
|
2018-04-13 16:38
-
1
2
3
4
5
6
7
8
9
10
다음
-
Back to Top